In today’s recent session, 1.34 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) have been traded, and its beta is 1.56. Most recently the company’s share price was $3.16, and it changed around -$0.54 or -14.46% from the last close, which brings the market valuation of the company to $210.56M. CRDF at last check was trading at a discount to its 52-week high of $5.64, offering almost -78.48% off that amount. The share price’s 52-week low was $2.01, which indicates that the recent value has risen by an impressive 36.39% since then. We note from Cardiff Oncology Inc’s average daily trading volume that its 10-day average is 1.19 million shares, with the 3-month average coming to 1.16 million.
Cardiff Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CRDF as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Cardiff Oncology Inc is expected to report earnings per share of -0.2 for the current quarter.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF has been showing red trend so far today with a performance of -14.46% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.99 on recent trading dayincreased the stock’s daily price by 20.8%. The company’s shares are currently down -27.07% year-to-date, but still down -18.11% over the last five days. On the other hand, Cardiff Oncology Inc (NASDAQ:CRDF) is 8.76% up in the 30-day period. We can see from the shorts that 17.63 million shares have been sold at a short interest cover period of 21.61 day(s).
Cardiff Oncology Inc (CRDF) estimates and forecasts
The year-over-year growth rate is expected to be -42.96%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 100k in revenue for the current quarter. 7 analysts expect Cardiff Oncology Inc to make 100k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 163k and 165k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -38.65%. Forecasts for the next quarter put sales growth at -39.39%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.36%. Cardiff Oncology Inc earnings are expected to increase by 13.83% in 2025, but the outlook is negative -8.77% per year for the next five years.
CRDF Dividends
Cardiff Oncology Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.64% of Cardiff Oncology Inc shares, and 45.28% of them are in the hands of institutional investors. The stock currently has a share float of 47.98%. Cardiff Oncology Inc stock is held by 143.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.8637% of the shares, which is about 2.63 million shares worth $5.84 million.
VANGUARD GROUP INC, with 4.766% or 2.14 million shares worth $4.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
